三突变肺癌中的表皮生长因子受体（EGFR）和 Kirsten 大鼠肉瘤病毒癌基因（KRAS）突变 - Suppr | 超能文献

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer.

作者信息

Yoshida Ryohei, Sasaki Takaaki, Ohsaki Yoshinobu

机构信息

Respiratory Center, Department of Pathology, Asahikawa Medical University, Hokkaido, Japan.

Respiratory Center, Department of Pathology, Asahikawa Medical University, Hokkaido, Japan.

出版信息

J Thorac Oncol. 2017 Jul;12(7):e92-e93. doi: 10.1016/j.jtho.2017.02.022.

DOI:10.1016/j.jtho.2017.02.022

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer.三突变肺癌中的表皮生长因子受体（EGFR）和 Kirsten 大鼠肉瘤病毒癌基因（KRAS）突变

J Thorac Oncol. 2017 Jul;12(7):e92-e93. doi: 10.1016/j.jtho.2017.02.022.

2

Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers.用于治疗 KRAS 突变型肺癌的药物联合疗法。

Curr Top Med Chem. 2019;19(23):2128-2142. doi: 10.2174/1568026619666190902150555.

3

Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.EGFR和KRAS突变型肺腺癌中TP53的突变及p14(arf)表达的改变。

Clin Lung Cancer. 2014 Mar;15(2):124-30. doi: 10.1016/j.cllc.2013.08.003. Epub 2013 Oct 26.

4

Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.EGFR 突变阴性非小细胞肺癌中 KRAS、BRAF、HER2 和 PTEN 的体细胞突变分析：印度患者中突变频率、分布模式的确定及 HER2 基因新型缺失的鉴定

Med Oncol. 2016 Oct;33(10):117. doi: 10.1007/s12032-016-0828-7. Epub 2016 Sep 16.

5

Same Name, Different Game: EGFR Drives Intrinsic KRAS Inhibitor Resistance in Colorectal Cancer.同名不同命：EGFR 驱动结直肠癌对 KRAS 抑制剂的内在耐药性。

Cancer Discov. 2020 Aug;10(8):1094-1096. doi: 10.1158/2159-8290.CD-20-0612.

6

Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?目前的诊断算法是否可靠，可用于选择进行肺癌中 EGFR 和 KRAS 基因突变分析的病例？

Lung Cancer. 2015 Jul;89(1):19-26. doi: 10.1016/j.lungcan.2015.04.005. Epub 2015 Apr 20.

7

About concomitant KRAS and other molecular alterations in non-small cell lung cancers.

Hum Pathol. 2019 May;87:115-116. doi: 10.1016/j.humpath.2019.01.003. Epub 2019 Feb 20.

8

Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations.基于皮升级液滴数字PCR的罕见突变多重检测：灵敏度和特异性考量

PLoS One. 2016 Jul 14;11(7):e0159094. doi: 10.1371/journal.pone.0159094. eCollection 2016.

9

[Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].基于2011年国际多学科肺腺癌分类的分子改变在肺腺癌组织病理学亚型中的相关性

Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):505-10. doi: 10.3760/cma.j.issn.0529-5807.2012.08.001.

10

Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS.鉴定影像表型与肺癌相关突变状态（EGFR 和 KRAS）之间的关系。

Sci Rep. 2020 Feb 27;10(1):3625. doi: 10.1038/s41598-020-60202-3.

引用本文的文献

1

The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer.循环肿瘤DNA分析作为三阴性乳腺癌复发标志物的可行性。

Oncol Lett. 2021 May;21(5):420. doi: 10.3892/ol.2021.12681. Epub 2021 Mar 28.